logo
St. Lucie school teams taking aim at Odyssey of Mind world title at Michigan competition

St. Lucie school teams taking aim at Odyssey of Mind world title at Michigan competition

Yahoo21-05-2025
ST. LUCIE COUNTY — How do you create a balsa wood structure that can support 805 pounds? Take lessons from a group of elementary students at Windmill Point Elementary School.
The students created a tower-type structure that can hold 805 pounds of weight as part of the Odyssey of the Mind competition. Now, along with a team from Morningside Elementary, they are going to the world competition on the Michigan State University campus in East Lansing.. It begins May 21.
Odyssey of the Mind is a competition that challenges elementary students to problem-solve and develop critical-thinking skills. Seven-member teams select a problem to solve based on a prompt, and then create a project and presentation around that prompt. Each project must be done 100% by the students. Any help from adult coaches and parents results in a penalty deducted from the team's overall score.
"It's the building and creativity and helping each other I like," said Abigail Rodgers, 10. "I liked all the teamwork."
Mason Black, 9, likes the challenge of the competition.
"I really like building things and making structures," he said. "It makes me feel like I can achieve things."
There are a lot of steps involved, he said.
"When it holds so much (weight), you know it's worth it," Mason said.
Students compete in regional and state competitions before taking their shot at the world competition.
At Windmill Point, students also used balsa wood to create a structure that could hold as much weight as possible. They also had to come up with a performance based on the theme of animal rescue, coaches Sean Caroglanian and Lacey Black explained.
The problem, according to the Odyssey of the Mind website, is to create a performance about an animal rescue character finding a home for balsa wood-and-glue animals created by the students. The performance has to include the rescue character testing how much weight the structure can hold and balance.
The performance also has to include an animal being seen by a veterinarian and the "creative" use of Arm & Hammer Baking Soda, the website said.
The Windmill Point team's structure weighed 18 grams and is about 8 inches tall. Over the course of the school year, the students created a few backup structures and practice designs. They created a koala bear, penguin and their own made-up animal resembling a polar bear with wings.
They used the baking soda to create a hairball for the koala bear to cough up.
Students were required to write the script and create the costumes and set for the performance, Caroglanian said. Coaches provided training on the use of power tools such as drills, a screwdriver and hammer, all while keeping within the rules of the competition.
The Morningside team selected from the "classics" category, building the project around "The Hobbit" by J.R.R. Tolkien. The team created a play around the book and created a cooking gadget on its own.
The students also needed to find a way to make a dragon by using utensils. Sporks seemed to be a good way to create dragon scales, explained Devyn Tran, 10.
"It's really fun, and we all get to work together," said Morningside Elementary student Jayda Matthews, 11. "I love coming up with creative solutions."
Devyn said he also likes the teamwork and the friendship he makes during the competition. He enjoyed helping build the set for the Morningside project, which included coming up with a type of flip table that makes the food in the play "magically appear."
He liked working on it at home "when I was bored," he added.
But the student projects also were limited to a budget set by the competition. The students decided to use used sporks, collected from their classmates from the cafeteria, he said.
Competing on the Odyssey of the Mind team takes a huge commitment from the students, coaches say.
"They have to be passionate about it," said Morningside Elementary coach Britt LaChance. Students spend months preparing their presentation and play, practicing twice a week. Once competition season comes around, teams practice three to four times a week.
Free VPK helps ready young children for school, but for some families it's unavailable
Nominate a favorite Treasure Coast teacher for TCPalm's Teacher of the Week poll
In addition to presenting their project, students also compete in a "spontaneous" component at the competition. They're given a problem and have to solve it creatively, working as a unit.
Sets need to be movable and able to be set up quickly. Teams are penalized if they go over the allotted eight minutes.
The students' costs, including registration and travel expenses, are paid for by the school district and by donations such as from the Boys & Girls Club.
Students were excited last week about traveling to Michigan, a first-time destination for some. They plan to trade pins with students from other teams. They've been paired with "buddy teams" from Hong Kong and Poland, and are excited about exchanging gifts from Florida and learning about other cultures.
Colleen Wixon is the education reporter for TCPalm and Treasure Coast Newspapers. She covers school districts in Indian River, Martin and St. Lucie counties.
This article originally appeared on Treasure Coast Newspapers: St. Lucie County schools sending two teams to world competition
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

Business Wire

time3 days ago

  • Business Wire

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, will host its virtual R&D Day today at 1:30 PM PT. The event will highlight the company's continued momentum in advancing its novel immunotherapy platforms—TRACTr and TRACIr, as well as ARM—designed to address significant unmet needs in oncology and autoimmune diseases. 'At Janux, we are guided by a deep commitment to scientific excellence and a belief that innovation should translate into meaningful outcomes for patients,' said David Campbell, Ph.D., President and CEO of Janux Therapeutics. 'The progress we've shared today across our TRACTr, TRACIr, and ARM platforms reflects our disciplined strategy to focus first on maximizing the benefit and value of our clinical program JANX007, second to harness the value of our clinical experience by bringing forward TRACTrs where we can potentially be first- and/or best-in-class, and third to utilize our T cell engager development expertise to enable platform technologies that address other clear gaps in the treatment landscape.' Creating an Opportunity to Further Differentiate JANX007 with TRACIr Combination Janux is advancing its CD28-based TRACIr platform designed to enhance T cell activation and durability of its CD3-based TRACTr platform. TRACIr was built on the same technology with the same tumor-activation and PK design features as TRACTr and combines tumor targeting with immune costimulation. The TRACIr platform represents a strategic extension of Janux's tumor-activated approach, designed to complement and enhance the clinical potential of its TRACTr portfolio, beginning with PSMA-TRACTr JANX007. While JANX007 has already demonstrated differentiated clinical activity in late-stage metastatic castration-resistant prostate cancer (mCRPC) patients, the addition of a PSMAxCD28-TRACIr introduces a costimulatory signal that may further enhance durability of response within the tumor microenvironment. This combination has the potential to drive more prolonged anti-tumor effects without increasing systemic toxicity, positioning Janux to further differentiate JANX007 in the mCRPC treatment landscape. IND-enabling studies are underway for the PSMA-TRACIr, with clinical trials in combination with JANX007 expected to begin in the second half of 2026. Expanding the TRACTr Platform into High-Value Oncology Indications Building upon learnings from the JANX007 and JANX008 clinical programs, Janux introduced its latest trophoblast cell surface antigen 2 (TROP2) TRACTr program. This next-generation TROP2-TRACTr was engineered for potential best-in-class safety and efficacy across a broad range of TROP2-expressing tumors, including breast, lung and bladder cancers. Janux's TROP2-TRACTr exemplifies the TRACTr technology's ability to create high-value T cell engager (TCE) product candidates directed at tumor targets that contemporary TCE technologies have been unable to access due to broad healthy tissue expression. Janux's TROP2-TRACTr product candidate demonstrated strong potency across multiple tumor types, activity at low TROP2 expression levels, and was well tolerated in non-human primates with no signs of cytokine release syndrome (CRS) or healthy tissue toxicity. This preclinical data also displayed the ability to overcome limitations of existing TROP2-targeted therapies, including antibody drug conjugates. These findings support a wide therapeutic window and the potential for best-in-class performance in TROP2-expressing solid tumors. IND-enabling activities are planned in the second half of 2025. ARM Platform Redefines T-Cell Engagers for Autoimmune Disease and Oncology Janux also introduced its Adaptive Immune Response Modulator (ARM) bispecific platform, designed to overcome the limitations of conventional TCEs in autoimmune diseases and oncology. Builds upon Janux's expertise to redesign bispecific TCEs. Differentiated non-clinical profile provides best-in-class opportunity in autoimmune diseases. Potential broad applicability across multiple disease areas. Large safety window and off-the-shelf format position it for higher dosing, rapid development and potential best-in-class performance. The lead program, a CD19-ARM, has displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, supporting a potential best-in-class profile. ARMs exhibit differentiated durable T cell activity with reduced T cell exhaustion preclinically. The program demonstrated prolonged memory B-cell depletion and immune reset from a single subcutaneous dose, reflecting the durability seen with CD19 CAR-T therapies but with greater safety and convenience. ARMs displayed potential to dose to maximum efficacy while enabling safer, outpatient-friendly dosing. In non-human primates, CD19-ARM achieved deep and durable B-cell depletion in both blood and lymphoid tissues with a >100x CRS safety window. The CD19-ARM is on track for first-in-human studies to begin in the first half of 2026. Event Information To join the webcast, please visit this link, or the Events & Presentations page of the Investors section on the Company's website A replay of the webcast will be archived and available following the event. Participant Dial-In Numbers: USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800) 715-9871 Conference ID 9235403 Janux's TRACTr, TRACIr and ARM Pipeline Janux's first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with mCRPC. Janux's second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. Janux is also advancing additional CD3-based TRACTr and CD28-based TRACIr programs for future clinical development, including a PSMA-TRACIr for use in combination with our PSMA-TRACTr JANX007, and a TROP2-TRACTr for the treatment of TROP2+ solid tumors. Janux is also advancing its first ARM platform program candidate, a CD19-ARM for the potential treatment of autoimmune diseases toward clinical trials. About Janux Therapeutics Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit and follow us on LinkedIn. Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux's ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux's development activities, including its ongoing and planned clinical trials, and the potential benefits of Janux's product candidates and platform technologies. Factors that may cause actual results to differ materially include the risk that interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations, the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words 'may,' 'will,' 'would,' 'could,' 'should,' 'believes,' 'estimates,' 'projects,' 'promise,' 'potential,' 'expects,' 'plans,' 'anticipates,' 'intends,' 'continues,' 'designed,' 'goal,' or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux's periodic and other filings with the Securities and Exchange Commission, which are available at Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Researchers pack a "quantum light factory" into a 1mm² CMOS chip — combines photonics, electronics, and quantum hardware with traditional silicon manufacturing that can achieve mass scale
Researchers pack a "quantum light factory" into a 1mm² CMOS chip — combines photonics, electronics, and quantum hardware with traditional silicon manufacturing that can achieve mass scale

Yahoo

time5 days ago

  • Yahoo

Researchers pack a "quantum light factory" into a 1mm² CMOS chip — combines photonics, electronics, and quantum hardware with traditional silicon manufacturing that can achieve mass scale

When you buy through links on our articles, Future and its syndication partners may earn a commission. Researchers from Boston University, UC Berkeley, and Northwestern University have created something that sounds straight out of a sci-fi movie: a 'quantum light factory' squeezed onto a 1 mm² silicon chip. Built using a standard 45 nm CMOS manufacturing process—the same kind used for standard x86 and ARM processors—this breakthrough brings quantum hardware a step closer to the world of mass production. The work, published in Nature Electronic, could pave the way for scalable quantum computing that doesn't require exotic setups, instead relying on mass production techniques that we already employ today. Think of this chip as a prototype for a future quantum factory line. It packs 12 tiny silicon loops, called "microring resonators," each acting as a generator of photon pairs with special quantum properties. These photon pairs are the lifeblood of many quantum technologies, but producing them usually requires fragile lab setups. Here, they're generated directly on a chip no bigger than a fingernail. What makes this remarkable is that the chip doesn't just produce quantum light; it's more about keeping that light stable. Microring resonators are powerful but temperamental—small temperature changes or manufacturing quirks can throw them out of tune, halting the photon flow. To solve this, the researchers built a feedback system directly into the chip; each resonator has a tiny photodiode to monitor its performance, along with miniature heaters and control circuits that adjust it on the fly. This self-tuning approach means all 12 resonators can work together in perfect sync, without the bulky stabilization equipment usually needed. 'This is a small step, but an important one,' said Miloš Popović, associate professor at Boston University and one of the senior authors. 'It shows we can build repeatable, controllable quantum systems in commercial semiconductor foundries.' That's the real story here—this isn't just a niche, bleeding-edge lab demo, but proof that quantum chips can be made with the same industrial techniques used to build CPUs and GPUs. Of course, quantum computing is nowhere near the maturity of standard semiconductors powering our devices today, but this is a step closer to that eventuality. Let's talk about the most important revelation. The team's choice of CMOS (Complementary Metal-Oxide-Semiconductor) is a game-changer. CMOS is the backbone of modern electronics, used by companies like TSMC to mass-produce everything from smartphones to supercomputers. While the 45 nm node used here isn't cutting-edge, it's proven, cost-effective, and compatible with the vast infrastructure of silicon manufacturing. The chip was built using a platform co-developed with GlobalFoundries and Ayar Labs, a company already leading the charge in optical interconnects for AI and high-performance computing. This overlap with the AI world is no coincidence. Nvidia CEO Jensen Huang recently called out microring resonators—like those on this chip—as key components for scaling AI hardware via optical connections. This new research shows that the same photonics technology could also unlock scalable quantum systems. It's not hard to imagine a future where quantum and AI hardware share similar silicon platforms. Moreover, Nvidia is already heavily investing in this field, so we can only expect development to ramp up. The term 'quantum light factory' isn't just for flair, either. Just as classical chips rely on streams of electrons and optical networks depend on laser light, future quantum technologies will need a steady supply of quantum light. By proving that these quantum light sources can be built, stabilized, and replicated on silicon, the team has shown that quantum hardware can move beyond one-off experiments and into something that can be scaled like traditional computing. Some of the researchers involved are already taking this expertise into industry roles. Team members have joined companies like PsiQuantum, Ayar Labs, and Google X, all of which are betting heavily on photonic and quantum technologies. It's another sign that this field is moving rapidly from academic research to real-world products, even if they're sometimes more fun-oriented than revolutionary. Backed by the National Science Foundation's Future of Semiconductors (FuSe) program, the Packard Fellowship, and the Catalyst Foundation, the project shows how far interdisciplinary collaboration can go. Photonics, electronics, and quantum optics are worlds apart, but this chip proves they can be brought together on a commercial platform. If Intel's 4004 microprocessor marked the start of mass-produced computing power, this 1 mm² quantum light factory could be remembered as the first step toward mass-produced quantum hardware. What once needed an entire lab bench now fits onto a silicon wafer—and that's a leap worth paying attention to. Who knows? Maybe a decade from now, you'll be seeing a new TSMC competing for quantum computing excellence, especially now that there's already an operating system for it out there. Follow Tom's Hardware on Google News to get our up-to-date news, analysis, and reviews in your feeds. Make sure to click the Follow button.

Lee Pace: Brother Day disillusioned with the Empire in 'Foundation' S3
Lee Pace: Brother Day disillusioned with the Empire in 'Foundation' S3

UPI

time19-07-2025

  • UPI

Lee Pace: Brother Day disillusioned with the Empire in 'Foundation' S3

1 of 4 | Lee Pace stars in "Foundaton." New episodes air Fridays. Photo courtesy of Apple TV+ NEW YORK, July 18 (UPI) -- The Hobbit and Guardians of the Galaxy actor Lee Pace says Season 3 of Foundation has a different feel than the previous two chapters of the critically acclaimed sci-fi drama. New episodes of the adaptation of Isaac Asimov's book series air Fridays on Apple TV+. The show follows a group of scientists who try to save humanity by rebuilding civilization on a remote planet amid the fall of the Galactic Empire, which is ruled by a genetic dynasty of three clones -- Pace's Brother Day, Terrence Mann's Brother Dusk and Cassian Milton's Brother Dawn. "He doesn't want any relationship with any of them. He's very disillusioned with the entire idea of Empire, that he's an emperor and he wants to get as far away from the jerks in the palace as he possibly can," Pace, 46, told UPI about Brother Day in a recent Zoom interview. "He wants to hang out in the garden and get stoned and eat and just be fat and happy," Pace explained. Answer the call. A new episode of #Foundation is now streaming. Apple TV (@AppleTV) July 18, 2025 "He doesn't want to sit there and play politics on the throne anymore and he hates the people who think that they can. He's not someone who thinks that it's worth trying to control anything. You can't do it. Not even the robot can do it. ... Might as well just relax. If things are going to fall apart, they're going to fall apart. There's no saving them." The Crow alum Laura Birn, 44, plays Demerzel, a humanoid robot and the trio's most trusted adviser. "I'm excited to explore the relationship between Demerzel and Day. I just find it endlessly interesting and surprising and disturbing this year," Birn said. "It's the part that I always wait most for when I get the new scripts, like, 'What's happening between them and this weird little dysfunctional family?'" Pace agreed. "i always find that really interesting and we have a great time working together, too, so it's such a fun dynamic to see: 'Well, what hands do we have this season? How is this game going to play out?'" he said. Season 3 sees the introduction of The Mule (Pilou Asbæk), a villain who uses mind control on his foes, but Pace said Brother Day doesn't even really know he exists. "He's too far away and insignificant," the actor added. "The Mule is the big instigator of the season and a very huge disruptor, but one of the things that's so interesting to me about Foundation is that it's not a story about battles. You might think that's the case from the beginning of this season where you've got a great, big, powerful Foundation and you've got a great, big, powerful Empire. You think they're going to clash in some way." But that's not actually where the story goes, Pace emphasized. "It's about the center falling out and then this crumbling over here and then that group kind of having a different opinion and eating each other," he said. "It's like the disintegration from lots of places. That's what chaos does to order," Pace added. "That's what The Mule is. He is the invention of chaos." Demerzel -- on the other hand -- thrives on mayhem. "The chaos and the destruction that he brings is kind of like another crisis to attack, to solve, but, at the same time, there's this weird possibility of freedom or something new or something unexpected for her," Birn noted. "She doesn't have clear answers," the actress added. "She's insecure of which direction is the right direction. Is her programming sending one direction or could it be this and that? And what happens? Her mind exploding for all these options is part of what The Mule offers for her. It is like the possibility to see things differently, so it definitely changes her course." So, is Foundation a cautionary tale for viewers in 2025? "I wouldn't want to tell anyone how to watch the show," Pace said. "The show is such a feast," he added. "You can pick and choose and think about things that resonate with you." The fact that the brilliant Hari Seldon (Jared Harris) has devised a way to protect and store all human knowledge on a safe planet is a positive message to impart to audiences. "At the center of the show is this idea of hope that Hari Selden proposes that there is a mathematical likelihood that we will survive this," Pace said. "It's not a zero chance that we will," he added. "There's a hope inside the show that I really appreciate. There's a sense of, 'You can bet on humans' ability to continue to travel on.'" Birn said she thinks her character's existence also makes the show relevant to people grappling with real-life issues connected to artificial intelligence. "We've created AI. We've taught AI everything it knows. But not even the ones who are creating it now have an idea where it will evolve and what happens if, suddenly, there's another species that's equal to us or even dominant," she added. "It's more than being afraid of AI, but more being a little bit afraid of how we will treat that other species, if it evolves." The cast also includes Lou Llobell, Cherry Jones, Brandon P. Bell, Synnøve Karlsen, Cody Fern, Tómas Lemarquis, Alexander Siddig and Troy Kotsur.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store